1
|
Martínez-Alfonzo I, Láinez-González D, Solán-Blanco L, Franganillo-Suarez A, Cornejo JI, Garcia-Lopez A, Martín-Herrero S, Castaño-Bonilla T, Salgado-Sánchez R, Arquero-Portero T, Cortti-Ferrari MJ, Llamas-Sillero P, Alonso-Dominguez JM. Flow Cytometry and Molecular Techniques Could Complement Morphological Detection of Leukemic Infiltration in Ascitic Fluids: A Case Report. Medicina (B Aires) 2022; 58:medicina58020264. [PMID: 35208587 PMCID: PMC8880337 DOI: 10.3390/medicina58020264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 01/27/2022] [Accepted: 02/08/2022] [Indexed: 11/16/2022] Open
Abstract
Extramedullary involvement of acute myeloid leukemia (AML) is infrequent, and ascitic infiltration is even more unusual. We present a case of a 48-year-old woman diagnosed with NPM1-mutated AML that debuted with ascites, for which morphological studies of the ascitic fluid did not detect leukemic infiltration, maybe due to technical problems in the sample preparation. Multiparameter flow cytometry (MFC) detected a blast population compatible with AML, and allele-specific PCR detected NPM1-mutated transcripts. Body fluid infiltrations are an infrequent initial manifestation or sign of progression in AML. As far as we know, this is the first reported case of an NPM1-mutated AML that debuted with ascites, and also the first description of the utilization of molecular techniques to detect the leukemic origin of the ascites. This case highlights that, given that allele-specific PCR and MFC increase the sensitivity of morphological studies, these techniques should be routinely applied in the study of any kind of effusion detected in an AML patient.
Collapse
Affiliation(s)
- Inés Martínez-Alfonzo
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Daniel Láinez-González
- Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 28040 Madrid, Spain;
| | - Laura Solán-Blanco
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Aida Franganillo-Suarez
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - José I. Cornejo
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain;
| | - Amanda Garcia-Lopez
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Sara Martín-Herrero
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Tamara Castaño-Bonilla
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Rocío Salgado-Sánchez
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Teresa Arquero-Portero
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - María J. Cortti-Ferrari
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
| | - Pilar Llamas-Sillero
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
- Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 28040 Madrid, Spain;
| | - Juan M. Alonso-Dominguez
- Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (I.M.-A.); (L.S.-B.); (A.F.-S.); (A.G.-L.); (S.M.-H.); (T.C.-B.); (R.S.-S.); (T.A.-P.); (M.J.C.-F.); (P.L.-S.)
- Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 28040 Madrid, Spain;
- Correspondence:
| |
Collapse
|
2
|
Yu T, Chi J, Wang L. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Hematology 2021; 26:848-859. [PMID: 34674615 DOI: 10.1080/16078454.2021.1990503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system. Residual leukemic cells after treatment are associated with relapse. Thus, detecting minimal residual disease (MRD) is significant. Major techniques for MRD assessment include multiparameter flow cytometry (MFC), polymerase chain reaction (PCR), and next-generation sequencing (NGS). At a molecular level, AML is the consequence of collaboration of several gene alterations. Some of these gene alterations can also be used as MRD markers to evaluate the level of residual leukemic cells by PCR and NGS. However, when as MRD markers, different gene alterations have different clinical values. This paper aims to summarize the characteristics of various MRD markers, so as to better predict the clinical outcome of AML patients and guide the treatment.
Collapse
Affiliation(s)
- Tingyu Yu
- Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China
| | - Jianxiang Chi
- Center for the Study of Hematological Malignancies, Nicosia, Cyprus
| | - Li Wang
- Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China
| |
Collapse
|
3
|
Othman GO, Mohammad NS, Saeed CH. Molecular study of Nucleophosmin 1(NPM1) gene in acute myeloid leukemia in Kurdish population. Afr Health Sci 2021; 21:687-692. [PMID: 34795724 PMCID: PMC8568245 DOI: 10.4314/ahs.v21i2.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND In patients with Acute Myeloid Leukemia (AML) the most frequent acquired molecular abnormalities and important prognostic indicators is nucleophosmin-1 (NPM1) mutations. Our study aims was molecular study of Nucleophosmin -1 gene in Acute Myeloid Leukemia in Kurdish population. PATIENTS &METHODS A total of 50 patients with AML, (36) of them attended Nanakaly Hospital and (14) attended Hiwa Hospital and 30 healthy subjects as control were selected randomly, all were matched of age and gender. Polymerase chain reaction (PCR) was used for detection of NPM1 gene mutation. Three samples of PCR product for NPM1 gene mutations were sequenced, and mutations were determined by comparison with the normal NPM1 sequence NCBI (GenBank accession number NM_002520). RESULTS Out of 50 patients with AML, 5 (10%) of them were NPM1 gene mutation positive, and 45 (90%) were negative. The mutation were a base substitution (C to A), (G to C), (G to T), transversion mutation in addition of frame shift mutation and all mutated cases were heterozygous and retained a wild type allele. CONCLUSION Identification of NPM1 mutations in AML are important for prognostication, treatment decision and optimization of patient care.
Collapse
Affiliation(s)
| | - Nawsherwan Sadiq Mohammad
- Hawler Medical University, College of Medicine. Nanakaly Teaching Hospital for Blood Diseases. Erbil- Iraq
| | | |
Collapse
|
4
|
Hoffmann H, Thiede C, Glauche I, Bornhaeuser M, Roeder I. Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach. J R Soc Interface 2020; 17:20200091. [PMID: 32900301 DOI: 10.1098/rsif.2020.0091] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Disease response and durability of remission are very heterogeneous in patients with acute myeloid leukaemia (AML). There is increasing evidence that the individual risk of early relapse can be predicted based on the initial treatment response. However, it is unclear how such a correlation is linked to functional aspects of AML progression and treatment. We suggest a mathematical model in which leukaemia-initiating cells and normal/healthy haematopoietic stem and progenitor cells reversibly change between an active state characterized by proliferation and chemosensitivity and a quiescent state, in which the cells do not divide, but are also insensitive to chemotherapy. Applying this model to 275 molecular time courses of nucleophosmin 1-mutated patients, we conclude that the differential chemosensitivity of the leukaemia-initiating cells together with the cells' intrinsic proliferative capacity is sufficient to reproduce both, early relapse as well as long-lasting remission. We can, furthermore, show that the model parameters associated with individual chemosensitivity and proliferative advantage of the leukaemic cells are closely linked to the patients' time to relapse, while a reliable prediction based on early response only is not possible based on the currently available data. Although we demonstrate with our approach, that the complete response data is sufficient to quantify the aggressiveness of the disease, further investigations are necessary to study how an intensive early sampling strategy may prospectively improve risk assessment and help to optimize individual treatments.
Collapse
Affiliation(s)
- H Hoffmann
- Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany
| | - C Thiede
- Medical Clinic and Polyclinic I, University Hospital Dresden Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - I Glauche
- Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany
| | - M Bornhaeuser
- Medical Clinic and Polyclinic I, University Hospital Dresden Carl Gustav Carus, TU Dresden, Dresden, Germany.,National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
| | - I Roeder
- Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.,National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
| |
Collapse
|
5
|
Zhu HR, Yu XN, Zhang GC, Shi X, Bilegsaikhan E, Guo HY, Liu LL, Cai Y, Song GQ, Liu TT, Dong L, Janssen HLA, Weng SQ, Wu J, Shen XZ, Zhu JM. Comprehensive analysis of long non‑coding RNA‑messenger RNA‑microRNA co‑expression network identifies cell cycle‑related lncRNA in hepatocellular carcinoma. Int J Mol Med 2019; 44:1844-1854. [PMID: 31485608 PMCID: PMC6777664 DOI: 10.3892/ijmm.2019.4323] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 07/24/2019] [Indexed: 12/30/2022] Open
Abstract
Long non-coding RNAs (lncRNAs) have been shown to contribute to progression and prognosis of hepatocellular carcinoma (HCC). However, expression profiling and interaction of lncRNAs with messenger RNAs (mRNAs) and microRNAs (miRNAs) remain largely unknown in HCC. The expression profiling of lncRNAs, mRNA and miRNAs was obtained using microarray. The Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis were used to characterize potential functions of differentially expressed mRNAs. Cytoscape was applied to construct an lncRNA-miRNA-mRNA co-expression network and candidate lncRNAs were validated via quantitative PCR in 30 pairs of HCC and adjacent tumor-free tissues. In this study, 1,056 upregulated and 1,288 downregulated lncRNAs were identified, while 2,687 mRNAs and 6 miRNAs were aberrantly expressed in HCC compared with adjacent tumor-free tissues. Potential functions of differentially expressed mRNAs were demonstrated to significantly participate in modulating critical genes in the cell cycle, such as cyclin E1 and cyclin B2. After screening, 95 lncRNAs, 5 miRNAs and 36 mRNAs were recruited for construction of lncRNA-mRNA-miRNA co-expression network in the cell cycle pathway. Subsequently, the top 5 lncRNAs that potentially modulate critical genes in the cell cycle were selected as the candidates for further verification. Kaplan-Meier curves using the Cancer Genome Atlas database showed that 13 targeted mRNAs were associated with overall survival of HCC patients. Finally, three lncRNAs, including ENST00000522221, lnc-HACE1-6:1 and lnc-ICOSLG-11:1, are significantly upregulated in HCC tissues compared with adjacent tumor-free tissues. These findings suggest that lncRNAs play essential roles in the pathogenesis of HCC via regulating coding genes and miRNAs, and may be important targets for diagnosis and treatment of this disease.
Collapse
Affiliation(s)
- Hai-Rong Zhu
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Xiang-Nan Yu
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Guang-Cong Zhang
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Xuan Shi
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Enkhnaran Bilegsaikhan
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Hong-Ying Guo
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Li-Li Liu
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Yu Cai
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Guang-Qi Song
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Tao-Tao Liu
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Ling Dong
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Harry L A Janssen
- Division of Gastroenterology, University of Toronto and University Health Network, Toronto, ON M5G 2C4, Canada
| | - Shu-Qiang Weng
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Jian Wu
- Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Xi-Zhong Shen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| | - Ji-Min Zhu
- Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
| |
Collapse
|
6
|
Li X, Xu DH, Liu F, Liu GY, Lu K, Deng XL, Li QF, Shi SL. Relocation of NPM Affects the Malignant Phenotypes of Hepatoma SMMC-7721 Cells. J Cell Biochem 2017; 118:3225-3236. [PMID: 28262969 DOI: 10.1002/jcb.25971] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Accepted: 03/01/2017] [Indexed: 12/20/2022]
Abstract
Nucleophosmin(NPM), heavily implicated in diverse solid tumors, is an important multifunctional protein mainly located in the nucleolus. Our previous study confirmed that NPM can also localize and accumulate in the cytoplasm of liver cancer cells. However, the role of cytoplasmic NPM (NPMc +) is unclear. Here, we showed that both nucleolar NPM and NPMc+ could promote cell proliferation, although the effect of NPMc+ was weaker than that of NPM. Cell adhesion ability of hepatoma cells was significantly reduced to a greater extent by NPMc+ expression. Nucleolar NPM enhanced cell migration and invasion, whereas NPMc+ impeded cell migration and invasion. The investigation of NPM interactional proteins by proteomic method demonstrated that the NPM was involved in multiple biological processes. By contrast, the interactional proteins of NPMc+ were mainly implicated in tRNA amino acylation regulation. The interactional network of NPMc+ was significantly small and simple. These results suggested that relocation of NPM altered its interactional network and consequently disturbed the primary functions, including cell proliferation, adhesion, migration, and invasion. NPM plays a promotional role in cancer and the reducing relocation may be a potential therapeutic target for hepatocellular carcinoma. J. Cell. Biochem. 118: 3225-3236, 2017. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Xiao Li
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| | - Dong-Hui Xu
- Department of Hepatic Biliary Pancreatic Vascular Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, P.R. China
| | - Fan Liu
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| | - Guo-Yan Liu
- Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University/Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian, P.R. China
| | - Kun Lu
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| | - Xiao-Ling Deng
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| | - Qi-Fu Li
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| | - Song-Lin Shi
- Department of Basic Medicine, Medical College of Xiamen University/Cancer Research Center of Xiamen University, Xiamen, 361102, P.R. China
| |
Collapse
|
7
|
Peterson LE, Kovyrshina T. Progression inference for somatic mutations in cancer. Heliyon 2017; 3:e00277. [PMID: 28492066 PMCID: PMC5415494 DOI: 10.1016/j.heliyon.2017.e00277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 03/08/2017] [Accepted: 03/23/2017] [Indexed: 01/05/2023] Open
Abstract
Computational methods were employed to determine progression inference of genomic alterations in commonly occurring cancers. Using cross-sectional TCGA data, we computed evolutionary trajectories involving selectivity relationships among pairs of gene-specific genomic alterations such as somatic mutations, deletions, amplifications, downregulation, and upregulation among the top 20 driver genes associated with each cancer. Results indicate that the majority of hierarchies involved TP53, PIK3CA, ERBB2, APC, KRAS, EGFR, IDH1, VHL, etc. Research into the order and accumulation of genomic alterations among cancer driver genes will ever-increase as the costs of nextgen sequencing subside, and personalized/precision medicine incorporates whole-genome scans into the diagnosis and treatment of cancer.
Collapse
Affiliation(s)
- Leif E. Peterson
- Center for Biostatistics, Houston Methodist Research Institute, Houston, TX 77030, USA
- Dept. of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA
- Dept. of Biostatistics, School of Public Health, University of Texas – Health Science Center, Houston, TX 77030, USA
- Dept. of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
- Dept. of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center, College Station, TX 77843, USA
| | - Tatiana Kovyrshina
- Center for Biostatistics, Houston Methodist Research Institute, Houston, TX 77030, USA
- Dept. of Mathematics and Statistics, University of Houston – Downtown, Houston, TX 77002, USA
| |
Collapse
|